ArticlePediatric nephrology (Berlin, Germany)2026
Patterns of kidney involvement after corticosteroid treatment for extrarenal symptoms in pediatric IgA vasculitis (Henoch-Schönlein Purpura): phenotypes and outcomes.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Corticosteroids in childhood IgA vasculitis: can early therapy mask kidney involvement?Pediatric nephrology (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorticosteroids are frequently used for extrarenal manifestations of Immunoglobulin A vasculitis (IgAV); however, their impact on the development and phenotypic pattern of kidney involvement remains unclear. We evaluated whether early steroid administration influences the incidence, timing, and phenotypic expression of kidney involvement.
methodsWe retrospectively analyzed pediatric IgAV patients at a tertiary center (2019-2025). Patients were stratified by whether systemic corticosteroids were administered within 4 weeks of extrarenal symptom onset. Outcomes included the incidence, timing, and phenotypic severity of kidney involvement and urinary normalization rates.
resultsAmong 211 patients (median follow-up duration: 2.43 [IQR 0.90-8.33] months), kidney involvement occurred in 20/92 (21.7%) of the steroid-treated and 14/119 (11.8%) of the non-steroid group without significant difference (p = 0.054, odds ratio 2.083, 95% CI 0.988-4.932). The steroid group exhibited significantly higher baseline disease severity, including gastrointestinal (73.9%, 68/92) and joint (67.4%, 62/92) symptoms and higher inflammatory markers, with no significant between-group difference in the median time to kidney involvement (1.03 vs. 0.72 months). However, steroid-treated patients were significantly more likely to present with microscopic hematuria and milder proteinuria (50.0% vs. 21.4%, p = 0.021) among kidney phenotypes. Notably, in the moderate proteinuria subgroup, none of the steroid-treated patients achieved full urinary normalization, compared with 75% of the non-steroid group.
conclusionsEarly corticosteroid treatment for extrarenal IgAV symptoms does not prevent, delay, or mask later kidney involvement. While it may shift the phenotypic expression toward milder hematuria-proteinuria patterns, it may not improve long-term urinary resolution in cases with more severe proteinuria.
Indexed as
Identifiers
42489915What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.